EP Patent

EP2131835A1 — Combinations of statins and anti-obesity agent

Assigned to Scidose LLC · Expires 2009-12-16 · 16y expired

What this patent protects

Co-therapy of an anti-obesity agent, a statin, is disclosed along with fixed combinations thereof. Atorvastatin and orlistat are preferred as the various components.

USPTO Abstract

Co-therapy of an anti-obesity agent, a statin, is disclosed along with fixed combinations thereof. Atorvastatin and orlistat are preferred as the various components.

Drugs covered by this patent

Patent Metadata

Patent number
EP2131835A1
Jurisdiction
EP
Classification
—
Expires
2009-12-16
Drug substance claim
No
Drug product claim
No
Assignee
Scidose LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.